Neuroendocrine Cancer
If it’s your first time on this website, please read the disclaimer section.
Oct 05 – Oct 12, 2026
Efficacy and Safety of Alectinib in Pediatric and Adult Patients with ALK-Altered Advanced Solid Tumors: a phase II TACKLE Trial (NCCH1712/MK003).
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
This open-label, multicenter phase II TACKLE trial evaluated alectinib in 26 pediatric and adult patients with advanced ALK-altered solid tumors across 11 tumor types. The primary endpoint was centrally confirmed objective response rate (ORR) per RECIST v1.1, assessed using a Bayesian design in patients receiving intact capsules (Cohort A). In Cohort A (n=16), ORR was 43.8%, meeting the primary endpoint; among all evaluable patients (n=24), ORR was 54.2% and DCR 75.0%, with median PFS of 24.9 months and OS of 38.8 months. Alectinib demonstrated meaningful, durable responses with acceptable safety (grade ≥3 TRAEs: 15.4%), supporting further tumor-agnostic development.
10.1158/1078-0432.CCR-26-1548
Sep 14 – Sep 21, 2026
Lurbinectedin plus irinotecan in pretreated gastroenteropancreatic neuroendocrine neoplasms: results of a phase II expansion cohort.
ESMO OPEN · Q1 JOURNAL - RANK #36/326
This phase II expansion cohort of a phase I/II trial evaluated lurbinectedin plus irinotecan in 34 pretreated patients with gastroenteropancreatic neuroendocrine neoplasms, including 20 poorly differentiated neuroendocrine carcinomas and 14 grade 2/3 well-differentiated neuroendocrine tumors. The primary endpoint was objective response rate; secondary endpoints included progression-free survival, overall survival, safety, and pharmacokinetics. In NEC patients, ORR was 15.0%, median PFS 3.1 months, and median OS 7.2 months; in NET patients, ORR was 7.1%, median PFS 3.4 months, and median OS 16.6 months. The combination showed antitumor activity in GEP-NECs but limited activity in GEP-NETs, with a predictable and manageable safety profile, warranting further exploration in GEP-NECs after platinum failure.
10.1016/j.esmoop.2026.108534
Aug 31 – Sep 07, 2026
Extended D3 Mesenterectomy in Small Bowel Cancer Treatment: Feasibility and Importance for Staging. First Results of a Prospective Clinical Trial.
WORLD J SURG · Q1 JOURNAL - RANK #70/312
This prospective clinical trial assessed the feasibility and staging implications of extended central (D3) mesenteric lymphadenectomy in 86 patients with small bowel cancer. Surgical techniques included preoperative 3D vascular mapping and standardized D3 resection of mesenteric tissue. D3 lymphadenectomy was achieved in 74 patients (86%), with a 7% reoperation rate (including 3% anastomotic leaks) and no 30-day mortality. Histopathology confirmed 60 small intestinal neuroendocrine tumors (siNETs) among 74 resected cases, with mesenteric lymph node metastases found in 62 patients (87%) and D3-volume metastases in 31 (44%). The authors conclude that D3 mesenterectomy is safe and radical, potentially improving staging accuracy and locoregional control, with subgroup analyses showing higher D3 positivity in proximal ileal siNETs (66%) compared to terminal ileal siNETs (29%).
10.1002/wjs.70550